BIOMARKERS IN SERUM, URIC ACID AS A RISK FACTOR FOR TYPE 2 DIABETES ASSOCIATED WITH HYPERTENSION

Authors

  • Tripathi Gk
  • Rachna Sharma
  • Manish Kumar Verma
  • Preeti Sharma
  • Pradeep Kumar Santosh University

Abstract

ABSTRACT
Objectives: Uric acid (UA) is the end product of purine metabolism in humans. UA is the final oxidation product of purine catabolism and has been
implicated in diabetes mellitus (DM) as well as in hyperlipidemias. Hyperuricemia can cause serious health problems including renal insufficiency.
Hyperuricemia is associated with many diseases including hypertension (HTN), DM, hypertriglyceridemia, and obesity. The aim was to determine the
serum UA (SUA) level in Patients of Type 2 DM with HTN.
Methods: Out of 100 samples, 50 were found as cases of Type 2 diabetic with HTN, and the 50 control samples were without Type 2 diabetic HTN.
Results: SUA, glycosylated hemoglobin, and low-density lipoprotein of male and female cases of Type 2 DM with HTN compared to control were
(p<0.05) highly significant and also serum triglycerides and total cholesterol of both sex groups of Type 2 DM with HTN compared to control were
found to be (p<0.05) highly significance.
Conclusion: It is concluded from our present study that level of SUA >7.0 mg/dl were significantly seen in cases of diabetes with HTN. SUA ≤5.0 mg/dl
was significantly seen in subjects without diabetes with HTN. Our data showed hyperuricemia and glycated hemoglobin as significant risk factors in
the progression of DM, atherosclerosis, myocardial infarction, renal disorder, hypertriglyceridemia, and obesity. Further large sample size studies are
needed to be done in the direction with more focused mechanistic approaches to fortify the fact. Very little is known about the relationship between
UA, DM, and HTN in India.
Keywords: Diabetes mellitus, Hypertension, Uric acid, Glycosylated hemoglobin, Lipid profile

Downloads

Download data is not yet available.

Author Biography

Pradeep Kumar, Santosh University

Professor of Biochemistry

References

REFERENCES

American Diabetes Association. Diagnosis and classification of

diabetes mellitus. Diabetes Care 2009;32 Suppl 1:S62-7.

Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum

uric acid level and long-term incidence of hypertension: Populationbased

cohort study.

J Hum Hypertens 2006;20(12):937-45.

Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA.

Serum uric acid. Its relationship to coronary heart disease risk factors

and cardiovascular disease, Evans County, Georgia. Arch Intern Med

;132(3):401-10.

Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the

relationship between fasting serum uric acid and the insulin sensitivity

index in a population-based sample of 380 young healthy Caucasians.

Eur J Endocrinol 1998;138(1):63-9.

Epstein M, Sowers JR. Diabetes mellitus and hypertension.

Hypertension 1992;19(5):403-18.

National high blood pressure education program working group report

on hypertension in diabetes. Hypertension 1994;23(2):145-58.

KDOQI. KDOQI clinical practice guidelines and clinical practice

recommendations for diabetes and chronic kidney disease. Am J

Kidney Dis 2007;49 2 Suppl 2:S12-154.

Hozawa A, Folsom AR, Ibrahim H, Nieto FJ, Rosamond WD,

Shahar E. Serum uric acid and risk of ischemic stroke: the ARIC study.

Atherosclerosis 2006;187(2):401-7.

Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and

risk for cardiovascular disease and death: the Framingham heart study.

Ann Intern Med 1999;131(1):7-13.

Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB,

Schmidt MI, Chambless LE. Risk factors for progression to incident

hyperinsulinemia: the atherosclerosis risk in communities study, 19871998.

Am

J Epidemiol 2003;158(11):1058-67.

Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High

serum uric acid as a novel risk factor for Type 2 diabetes. Diabetes Care

;31(2):361-2.

Iliesiu A, Campeanu A, Dinu D. Serum uric acid and cardiovascular

disease. J Clin Med 2010;5(3):186-92.

American Diabetes Association. Diagnosis and classification of

diabetes mellitus. Diabetic Care 2012;35(1):64-71.

McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, et al.

National Clinical Guideline for Management in Primary and Secondary

Care. Type 2 Diabetes. No. 1. London: Royal College of Physicians;

p. 259.

World Health Organization Consultation. Definition, Diagnosis and

Classification of Diabetes Mellitus and its Complications. WHO/NCD/

NCS/99.2. No. 1. World Health Organization. Geneva: Department of

Non-Communicable Disease Surveillance; 1999. p. 49.

Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM.

Glycated hemoglobin: methodologies and clinical applications. Clin

Chem 1986;32 10 Suppl: B64-70.

Varly H, Gowenlock AH, Bell M. Practical Clinical Biochemistry.

ed. London: Heinemann Medical; 1980. p. 650-7.

Teitz NW. Clinical Guide to Laboratory Tests. 3

th

ed. Philadelphia,

USA: W.E. Saunders; 1995. p. 610.

rd

Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic

determination of total serum cholesterol. Clin Chem 1974;20(4):470-5.

Teitz NW. Clinical Guide to Laboratory Tests. 3rd ed. Philadelphia,

USA: W.E. Saunders; 1995. p. 130.

Xiao H. Method and Composition for Determining High Density

Lipoprotein Cholesterol. Chinese Patent CN1379235A; 2002.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the

concentration of low-density lipoprotein cholesterol in plasma, without

use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.

Tietz NW, editor. Clinical Guide to Laboratory Tests. 2nd ed.

Philadelphia: W.B. Saunders; 1990. p. 566.

Bagnati M, Cristina P, Cristiana CA, Roberta B, Emanuele A, Giorgio B.

When and why a water-soluble antioxidant becomes pro-oxidant

during a copper-induced, low-density lipoprotein oxidation: A study

which was done by using uric acid. Biochem J 1999;340:143-52.

Strasak AM, Rapp K, Hilbe W, Oberaigner W, Ruttmann E, Concin H,

Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 352-355

Tripathi et al.

et al. The role of serum uric acid as an antioxidant protecting against

cancer: prospective study in more than 28 000 older Austrian women.

Ann Oncol 2007;18(11):1893-7.

Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K.

Serum uric acid and risk for development of hypertension and impaired

fasting glucose or Type II diabetes in Japanese male office workers. Eur

J Epidemiol 2003;18(6):523-30.

Alam R, Verma MK, Verma P. Glycated hemoglobin as a dual

biomarker in Type 2 diabetes mellitus predicting glycemic control and

dyslipidemia risk. Int J Life Sci Sci Res 2015;1(2):62-5.

Çağlı K, Turak O, Canpolat U, Özcan F, Tok D, Mendi MA, et al.

Association of serum uric acid level with blood pressure variability

in newly diagnosed essential hypertension. J Clin Hypertens

;17(12):929-35.

Published

01-03-2016

How to Cite

Gk, T., R. Sharma, M. Kumar Verma, P. Sharma, and P. Kumar. “BIOMARKERS IN SERUM, URIC ACID AS A RISK FACTOR FOR TYPE 2 DIABETES ASSOCIATED WITH HYPERTENSION”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 352-5, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/10915.

Issue

Section

Original Article(s)